• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.

作者信息

Younis Tallal, Skedgel Chris

机构信息

Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.

出版信息

Pharmacoeconomics. 2011 May;29(5):361-5. doi: 10.2165/11588350-000000000-00000.

DOI:10.2165/11588350-000000000-00000
PMID:21504237
Abstract
摘要

相似文献

1
Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.乳腺癌辅助曲妥珠单抗治疗：HERA试验提前终止后的临床及经济学证据的不确定性
Pharmacoeconomics. 2011 May;29(5):361-5. doi: 10.2165/11588350-000000000-00000.
2
The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.早期乳腺癌辅助性曲妥珠单抗的成本效益问题。
Expert Opin Pharmacother. 2006 Aug;7(12):1617-25. doi: 10.1517/14656566.7.12.1617.
3
Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?辅助性乳腺癌曲妥珠单抗治疗所带来的巨大益处是否能抵消其高昂成本？
J Clin Oncol. 2007 Feb 20;25(6):611-3. doi: 10.1200/JCO.2006.09.3542.
4
An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.曲妥珠单抗辅助治疗 HER2 阳性早期乳腺癌的经济学评价。
Value Health. 2009 Nov-Dec;12 Suppl 3:S82-4. doi: 10.1111/j.1524-4733.2009.00634.x.
5
How much will Herceptin really cost?赫赛汀的实际费用会是多少？
BMJ. 2006 Nov 25;333(7578):1118-20. doi: 10.1136/bmj.39008.624051.BE.
6
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.曲妥珠单抗治疗早期乳腺癌的成本效益分析更新：从英国角度考虑获益持续时间、长期毒性和复发模式。
Pharmacoeconomics. 2011 May;29(5):415-32. doi: 10.2165/11588340-000000000-00000.
7
Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.曲妥珠单抗：早期乳腺癌应用的药物经济学综述
Pharmacoeconomics. 2008;26(8):699-719. doi: 10.2165/00019053-200826080-00006.
8
When an interim analysis of randomized trial changes the practice in oncology: the lesson of adjuvant Trastuzumab and the HERA trial.随机试验的中期分析改变肿瘤学实践：辅助曲妥珠单抗和 HERA 试验的教训。
Immunopharmacol Immunotoxicol. 2009 Mar;31(1):30-1. doi: 10.1080/08923970802340332.
9
Adjuvant trastuzumab for breast cancer: an increasingly common ethical and economic conundrum.乳腺癌辅助性曲妥珠单抗治疗：一个日益常见的伦理和经济难题。
BMJ. 2005 Nov 19;331(7526):1202. doi: 10.1136/bmj.331.7526.1202-b.
10
Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.曲妥珠单抗在早期乳腺癌辅助治疗中的成本效益：一项终生模型研究
Pharmacoeconomics. 2007;25(5):429-42. doi: 10.2165/00019053-200725050-00006.

本文引用的文献

1
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.曲妥珠单抗治疗早期乳腺癌的成本效益分析更新：从英国角度考虑获益持续时间、长期毒性和复发模式。
Pharmacoeconomics. 2011 May;29(5):415-32. doi: 10.2165/11588340-000000000-00000.
2
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.曲妥珠单抗辅助化疗后治疗 1 年用于人表皮生长因子受体 2 阳性早期乳腺癌患者：一项随机对照试验的 4 年随访。
Lancet Oncol. 2011 Mar;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X. Epub 2011 Feb 25.
3
Clinical trials: discerning hype from substance.
临床试验：甄别炒作与实质。
Ann Intern Med. 2010 Sep 21;153(6):400-6. doi: 10.7326/0003-4819-153-6-201009210-00008.
4
Optimizing the management of HER2-positive early breast cancer: the clinical reality.优化 HER2 阳性早期乳腺癌的管理：临床现实。
Curr Oncol. 2010 Aug;17(4):20-33. doi: 10.3747/co.v17i4.700.
5
Is trastuzumab a cost-effective treatment for breast cancer?曲妥珠单抗治疗乳腺癌是否具有成本效益？
Expert Rev Pharmacoecon Outcomes Res. 2008 Oct;8(5):433-42. doi: 10.1586/14737167.8.5.433.
6
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis.提前停止随机试验以获得益处和估计治疗效果：系统评价和荟萃回归分析。
JAMA. 2010 Mar 24;303(12):1180-7. doi: 10.1001/jama.2010.310.
7
Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.回顾 2005 年 7 月至 2007 年 12 月期间美国食品药品监督管理局批准的肿瘤学和血液学药物产品。
J Natl Cancer Inst. 2010 Feb 24;102(4):230-43. doi: 10.1093/jnci/djp515. Epub 2010 Jan 29.
8
Design and analysis issues for economic analysis alongside clinical trials.与临床试验同时进行的经济分析的设计与分析问题。
Med Care. 2009 Jul;47(7 Suppl 1):S14-20. doi: 10.1097/MLR.0b013e3181a31971.
9
The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.曲妥珠单抗辅助治疗 Her2/Neu 阳性乳腺癌的成本-效用：基于 HERA 试验更新结果的分析。
Value Health. 2009 Jul-Aug;12(5):641-8. doi: 10.1111/j.1524-4733.2009.00511.x.
10
Stopping clinical trials early for benefit: impact on estimation.因有益而提前终止临床试验：对估计的影响。
Clin Trials. 2009 Apr;6(2):119-25. doi: 10.1177/1740774509102310.